Tiaprofenic Acid

Summary

Tiaprofenic Acid (CHEMBL365795) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AE11); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AE11
• Indications: 1 condition
• Chemistry: 260.31 Da · C14H12O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL365795
Name	Tiaprofenic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5468
ChEBI	CHEBI:32221
ATC	M01AE11
Molecular formula	C14H12O3S
Molecular weight	260.31
InChIKey	GUHPRPJDBZHYCJ-UHFFFAOYSA-N

SMILES: CC(C1=CC=C(S1)C(=O)C2=CC=CC=C2)C(=O)O

IUPAC name: 2-(5-benzoylthiophen-2-yl)propanoic acid

ChEBI definition: An aromatic ketone that is thiophene substituted at C-2 by benzoyl and at C-4 by a 1-carboxyethyl group.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, drug allergen.

Also known as: Acide tiaprofenique, Acido tiaprofenico, RU-15060, Surgam, Surgam 200, Surgam 300, Surgam sa, Tiaprofen, Tiaprofenate, Tiaprofenic acid, SID56463054, tiaprofenic

Patent coverage: 4,728 distinct patent families (19,194 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Alpha-2C adrenergic receptor, Amine oxidase [flavin-containing] A, Alpha-1A adrenergic receptor, D(3) dopamine receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q63921	6.44	AC50	365	nM	CHEMBL_ACT_25174527
DRD3	5.07	AC50	8600	nM	CHEMBL_ACT_25193662
KCNH2	5.03	AC50	9257	nM	CHEMBL_ACT_25118059
ADRA1A	5	AC50	10030	nM	CHEMBL_ACT_25138019

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).